St. Luke's Episcopal Hospital Becomes First in Texas to Monitor Post-surgical Patients With Masimo Patient SafetyNet(TM)
2010年1月27日 - 1:00AM
PRニュース・ワイアー (英語)
Clinically-Proven Technology Helps St. Luke's Clinicians Improve
Patient Care and Reduce Costs HOUSTON, Jan. 26
/PRNewswire-FirstCall/ -- St. Luke's Episcopal Hospital (SLEH) and
Masimo (NASDAQ:MASI), the inventor of Pulse CO-Oximetry(TM) and
Measure-Through Motion and Low-Perfusion pulse oximetry, jointly
announced today that the Houston-based hospital is the first in
Texas to use the Masimo Patient SafetyNet(TM) system to
continuously monitor the physiological status of post-surgical
patients -- ensuring early detection of patient deterioration and
enabling potentially life-saving interventions. With the Patient
SafetyNet system, St. Luke's clinicians receive a pager
notification when a patient's condition is worsening, allowing them
to intervene before the condition becomes critical and requires
more acute levels of care. This is particularly important for
post-surgical patients who are at increased risk of serious injury
or death resulting from the respiratory depression effects of
patient-controlled analgesia (PCA) and opioids used for sedation
and pain management. According to John Sabo, administrative
director of Respiratory Therapy at St. Luke's Episcopal Hospital,
Masimo Patient SafetyNet is helping St. Luke's to realize its
vision of improving both patient safety and hospital efficiencies
through early detection and intervention of acute respiratory
changes in its post-surgical patients. "We have already witnessed
the benefits of Patient SafetyNet in our orthopedic and pulmonary
units. Patient SafetyNet will assist in the improvement of
utilization of ICU resources, patient outcomes, and a reduction in
overall costs." The Patient SafetyNet system keeps post-surgical
patients safer by continuously, noninvasively, and remotely
monitoring multiple physiological parameters, including arterial
oxygen saturation and pulse rate, and automatically alerting
clinicians to changes that signal patient distress or
deterioration. In a recently published landmark study by Dartmouth
Hitchcock Medical Center, the Patient SafetyNet system was shown to
help reduce rescue events and activations 65% and ICU transfers
48%.(1) "Once my alarm limits are set, I know I can rely on Patient
SafetyNet to watch over my patients, continuously assessing their
health status 24/7," stated Samantha Biba, BSN, RN-BC, Acute
Pulmonary Unit, Quality Supervisor. "At the first sign of trouble,
the system alerts me via pager so I can attend to the patient and
assess his or her condition. Not only has the system been
instrumental in helping us to identify patient deterioration much
earlier to prevent more serious adverse events, but its effect on
patient care and safety has been invaluable." Combining the gold
standard performance of Masimo SET® pulse oximetry with respiration
rate monitoring at the point-of-care and wireless clinician
notification via pager, Patient SafetyNet provides an unmatched
level of safety for up to 80 patients on four floors. The system
uses open IEEE industry standards for connectivity, which allows
for more efficient sharing of data across a hospital's IT
platforms, along with the option of full integration into a
hospital's existing IT infrastructure -- providing a lower overall
cost of ownership and improved financial benefits. To further
advance patient safety initiatives, St. Luke's will also implement
Masimo Rainbow SET Pulse CO-Oximetry technology -- making
noninvasive and continuous hemoglobin (SpHb(TM)), oxygen content
(SpOC(TM)), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and
PVI® an integral component of their routine patient monitoring
protocols in their emergency, surgery, and recovery care areas. (1)
Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike,
George T. "Impact of Pulse Oximetry Surveillance on Rescue Events
and Intensive Care Unit Transfers: A Before-and-After Concurrence
Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available
online at:
http://journals.lww.com/anesthesiology/Abstract/publishahead/Impact_of_Pulse_O
ximetry_Surveillance_on_Rescue.99692.aspx About St. Luke's
Episcopal Health System St. Luke's Episcopal Health System
(http://www.stlukestexas.com/) includes St. Luke's Episcopal
Hospital in the Texas Medical Center, founded in 1954 by the
Episcopal Diocese of Texas; St. Luke's The Woodlands Hospital; St.
Luke's Sugar Land Hospital; St. Luke's Lakeside Hospital; St.
Luke's Episcopal Health Charities, a charity devoted to assessing
and enhancing community health, especially among the underserved.
St. Luke's Episcopal Hospital is home to the Texas Heart®
Institute, which was founded in 1962 by Denton A. Cooley, MD, and
is consistently ranked among the top 10 cardiology and heart
surgery centers in the country by U.S.News & World Report.
Affiliated with several nursing schools and three medical schools,
St. Luke's Episcopal Hospital was the first hospital in Texas named
a Magnet hospital for nursing excellence, and has been honored four
times with the Distinguished Hospital Award for Clinical
Excellence(TM) by HealthGrades, a leading independent company that
measures healthcare quality in hospitals. The Health System has
been recognized by FORTUNE as among the "100 Best Companies to Work
For" and by the Houston Business Journal as a top employer in
Houston. St. Luke's Episcopal Health System also was honored as one
of Modern Healthcare magazine's "100 Best Places to Work." About
Masimo Masimo (NASDAQ:MASI) develops innovative monitoring
technologies that significantly improve patient care -- helping
solve "unsolvable" problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as
Masimo SET®, which virtually eliminated false alarms and increased
pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements even
under the most challenging clinical conditions, including patient
motion and low peripheral perfusion. In 2005, Masimo introduced
Masimo Rainbow SET® Pulse CO-Oximetry(TM), allowing noninvasive and
continuous monitoring of blood constituents that previously
required invasive procedures, including total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI®, in addition to SpO2, pulse rate,
and perfusion index (PI). In 2009, Masimo introduced Masimo Rainbow
SET® Acoustic Monitoring(TM), the first-ever noninvasive and
continuous monitoring of acoustic respiration rate (RRa). Masimo's
Rainbow platform offers a breakthrough in patient safety by helping
clinicians detect life-threatening conditions and helping guide
treatment options. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking
Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at
http://www.masimo.com/. Forward Looking Statements This press
release includes forward-looking statements as defined in Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
based on current expectations about future events affecting us and
are subject to risks and uncertainties, all of which are difficult
to predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
belief that Masimo Patient SafetyNet will provide an effective
early warning system of a patient's deteriorating physiological
condition to enable timely rescue and increase patient safety,
risks related to our belief that Masimo SET and Masimo Rainbow SET
measurements and alarms will provide sufficient sensitivity and
specificity to detect physiological abnormalities and potentially
life-threatening conditions in real-time for all patients, risks
related to our assumptions regarding the repeatability of clinical
results, as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at http://www.sec.gov/. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk
Factors" contained in our most recent reports filed with the SEC,
whether as a result of new information, future events or otherwise,
except as may be required under the applicable securities laws.
Media Contacts: Dana Banks Jessica Michan Masimo Corporation St.
Luke's Episcopal Health System (949) 297-7348 (832) 355-3791
Masimo, SET, Signal Extraction Technology, Improving Outcomes and
Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa,
Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry
and Pulse CO-Oximeter are trademarks or registered trademarks of
Masimo Corporation. DATASOURCE: Masimo Corporation CONTACT: Dana
Banks of Masimo Corporation, +1-949-297-7348, ; or Jessica Michan
of St. Luke's Episcopal Health System, +1-832-355-3791, Web Site:
http://www.masimo.com/ http://www.sleh.com/
Copyright